文献速递淋巴瘤

早期低危儿童霍奇金淋巴瘤慢早期反应者的靶向放疗:COG AHOD0431 分析

Targeted radiotherapy for early-stage, low-risk pediatric Hodgkin lymphoma slow early responders: a COG AHOD0431 analysis.
PubMed 文献 · Blood · 2022-01-01

COG AHOD0431 试验在早期儿童经典型霍奇金淋巴瘤中减少全身治疗并采用反应适应性受累野放疗(IFRT)。分析显示,快速早期反应者(RER)10年无进展生存率(PFS)接受IFRT为96.6%、未接受为84.1%(P=0.10);慢早期反应者(SER)接受IFRT为80.9%、未接受为64.0%(P=0.03)。SER单独AVPC化疗结局不佳,但21-Gy IFRT可改善。

要点

  • SER接受IFRT的10年PFS为80.9%,未接受IFRT为64.0%(P=0.03)。
  • RER接受IFRT的10年PFS为96.6%,未接受IFRT为84.1%(P=0.10)。
  • SER未接受IFRT者16次复发中14次位于初始部位,其中9次仅位于PET1+部位。

核心结论

  • SER单独接受3周期AVPC化疗结局不佳,但接受21-Gy IFRT后改善;放疗仍是SER治疗的重要组成部分。

研究设计与样本

  • COG AHOD0431试验分析早期儿童经典型霍奇金淋巴瘤患者,中位随访118个月。
  • 患者接受AVPC(多柔比星、长春新碱、泼尼松、环磷酰胺)1周期后行PET1反应评估,PET1阴性为RER,阳性为SER。
  • 3周期化疗后CT和功能成像部分缓解者接受21-Gy IFRT,完全缓解者不接受IFRT。

主要发现

  • RER接受IFRT的10年PFS为96.6%,未接受IFRT为84.1%(P=0.10)。
  • SER接受IFRT的10年PFS为80.9%,未接受IFRT为64.0%(P=0.03)。
  • 90例未接受IFRT的RER中,14次复发均涉及初始部位。
  • 45例未接受IFRT的SER中,16次复发有14次位于初始部位,其中9次仅位于PET1+部位。
  • 58例接受IFRT的患者中,10次复发有5次位于PET1+部位。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Children's Oncology Group (COG) trial AHOD0431 reduced systemic therapy and used response-adapted involved-field radiotherapy (IFRT) in early-stage pediatric classic Hodgkin lymphoma. We investigated the impact of positron emission tomographic response after 1 cycle (PET1) and on IFRT outcomes and pattern of relapse. Patients in AHOD0431 underwent PET1 response assessment after AVPC (doxorubicin, vincristine, prednisone, and cyclophosphamide). "Rapid early responders" (RERs) had a negative PET1 (PET1-); "slow early responders" (SERs) had a positive PET1 (PET1+). Patients with a partial response by computed tomographic and functional imaging after 3 chemotherapy cycles received 21-Gy IFRT, whereas complete responders had no IFRT. Progression-free survival (PFS) was evaluated for RERs and SERs treated with or without IFRT. Recurrence sites were initial, new, or both. Relapses involving initial sites were characterized as "within the PET1+ site" or "initially involved but outside the PET1+ site." Median follow-up was 118 months. The 10-year PFS rate among RERs was 96.6% with IFRT and 84.1% without IFRT (P = .10), whereas SERs were 80.9% with IFRT and 64.0% without IFRT (P = .03). Among 90 RERs who did not receive IFRT, all 14 relapses included an initial site. Among 45 SERs receiving no IFRT, 14 of 16 relapses were in the initial site (9 PET1+ site only). Among 58 patients receiving IFRT, 5 of 10 relapses were in the PET1+ site. After 3 cycles of AVPC alone, RERs showed favorable results. Conversely, SERs had unfavorable outcomes with AVPC alone, although they improved with 21-Gy IFRT. RT remains an important component of treatment for SERs. This trial was registered at www.clinicaltrials.gov as #NCT00302003.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Parekh A, Keller FG, McCarten KM, et al. Targeted radiotherapy for early-stage, low-risk pediatric Hodgkin lymphoma slow early responders: a COG AHOD0431 analysis. Blood. 2022. PMID: 35763667. doi:10.1182/blood.2022016098

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。